During the past decade, Wojewodzki Szpital Specjalistyczny w Olsztynie conducted 29 clinical trials. In the 10-year time frame, 29 clinical trials started and 14 clinical trials were completed, i.e. on average, 48.3% percent of trials that started reached the finish line to date. In the past 5 years, 11 clinical trials started and 12 clinical trials were completed. i.e. 109.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Wojewodzki Szpital Specjalistyczny w Olsztynie" #1 sponsor was "Celgene" with 6 trials, followed by "Hoffmann-La Roche" with 5 trials sponsored, "Janssen Research & Development, LLC" with 4 trials sponsored, "Eli Lilly and Company" with 3 trials sponsored and "AstraZeneca" with 3 trials sponsored. Other sponsors include 14 different institutions and companies that sponsored additional 20 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Wojewodzki Szpital Specjalistyczny w Olsztynie" #1 collaborator was "Merck Sharp & Dohme LLC" with 2 trials as a collaborator, "Myriad Genetic Laboratories, Inc." with 2 trials as a collaborator, "Syneos Health" with 2 trials as a collaborator, "European Network of Gynaecological Oncological Trial Groups (ENGOT)" with 1 trials as a collaborator and "Foundation Medicine" with 1 trials as a collaborator. Other collaborators include 4 different institutions and companies that were collaborators in the rest 14 trials.

According to Clinical.Site data, the most researched conditions in "Wojewodzki Szpital Specjalistyczny w Olsztynie" are "Ovarian Cancer" (5 trials), "Ulcerative Colitis" (5 trials), "Crohn Disease" (4 trials), "Peritoneal Cancer" (3 trials) and "Relapsing Multiple Sclerosis" (3 trials). Many other conditions were trialed in "Wojewodzki Szpital Specjalistyczny w Olsztynie" in a lesser frequency.

Most popular intervention types in "Wojewodzki Szpital Specjalistyczny w Olsztynie" are "Drug" (34 trials), "Biological" (7 trials), "Other" (4 trials), "Dietary Supplement" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (16 trials), "Ozanimod" (5 trials), "Guselkumab" (3 trials), "Etrolizumab" (2 trials) and "Golimumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Wojewodzki Szpital Specjalistyczny w Olsztynie" are 31 trials for "All" genders and 8 trials for "Female" genders.

Currently, there are NaN active trials in "Wojewodzki Szpital Specjalistyczny w Olsztynie". undefined are not yet recruiting, 15 are recruiting, 5 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 14 completed trials in Wojewodzki Szpital Specjalistyczny w Olsztynie, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Wojewodzki Szpital Specjalistyczny w Olsztynie, 0 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 35 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".